While many have heard the headlines surrounding Johnson & Johnson (NYSE:JNJ) and problems with its metal hip replacements, the company's subsidiary Ethicon has more than 2,000 lawsuits pending concerning a different medical device -- vaginal mesh, which is used to give support to a patient's pelvic organs in cases of pelvic organ prolapse. In this video, Motley Fool health care bureau chief Brenton Flynn tells investors how much money could be at stake here for the company, and whether this is news to care about or just noise.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
